Ignite Creation Date:
2024-05-06 @ 5:46 PM
Last Modification Date:
2024-10-26 @ 2:35 PM
Study NCT ID:
NCT05429320
Status:
RECRUITING
Last Update Posted:
2024-06-13
First Post:
2022-06-15
Brief Title:
A Study of Local Ablative Therapy LAT in People With Non-Small Cell Lung Cancer NSCLC
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
A Phase II Adaptive Study of Local Ablative Therapy LAT for Patients With Metastatic Non-Small Cell Lung Cancer NSCLC Using Minimal Residual Disease MRD as an Integral Biomarker
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see whether receiving local ablative therapy LAT when minimal residual diseaseMRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancerNSCLC longer compared to systemic therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None